UNRESECTABLE MELANOMA
Clinical trials for UNRESECTABLE MELANOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE MELANOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Modified virus targets Hard-to-Treat melanoma in early trial
Disease control TerminatedThis early-phase trial tested a specially modified virus (VSV-IFNb-TYRP1) in 12 people with advanced melanoma that had spread or couldn't be removed. The virus was injected directly into tumors and into a vein to see if it could safely trigger the immune system to attack cancer c…
Matched conditions: UNRESECTABLE MELANOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 04:38 UTC
-
Experimental combo for advanced melanoma shows promise but study halted early
Disease control TerminatedThis study tested a new drug combination for people with advanced melanoma that cannot be removed by surgery or has spread. The experimental treatment involved injecting CMP-001 directly into tumors along with the immunotherapy nivolumab, compared to nivolumab alone. The study wa…
Matched conditions: UNRESECTABLE MELANOMA
Phase: PHASE2, PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
Melanoma drug combo trial halted early – what happened?
Disease control TerminatedThis study tested a combination of two drugs (duvelisib and nivolumab) in 13 people with advanced melanoma that had stopped responding to standard immunotherapy. The goal was to find a safe dose and see if the combo could shrink tumors. The trial was terminated early, so results …
Matched conditions: UNRESECTABLE MELANOMA
Phase: PHASE1, PHASE2 • Sponsor: John Kirkwood • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
Melanoma study halted early: could a malaria drug help cancer treatment?
Disease control TerminatedThis study looked at adding hydroxychloroquine (a malaria drug) to standard targeted therapy (dabrafenib and trametinib) for people with advanced BRAF V600E/K melanoma that had high LDH levels. The goal was to see if the combination could delay cancer growth. Only 5 people enroll…
Matched conditions: UNRESECTABLE MELANOMA
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 20, 2026 11:53 UTC